<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141023</url>
  </required_header>
  <id_info>
    <org_study_id>PPMI-001</org_study_id>
    <nct_id>NCT01141023</nct_id>
  </id_info>
  <brief_title>Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression</brief_title>
  <acronym>PPMI</acronym>
  <official_title>The Parkinson's Progression Markers Initiative (PPMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ken Marek, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Michael J. Fox Foundation for Parkinson's Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a observational, multi-center study to assess progression of clinical features,
      imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy
      controls (HC) and in PD patient subtypes.

      The primary objective of this study is to identify clinical, imaging and biologic markers of
      PD progression for use in clinical trials of disease-modifying therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amendment 14 - 26-Mar-2018 Revised to reflect the implementation of PPMI Wearables and Sensor
      Study Companion Protocol

      Amendment 13 - 20-Nov-2017 Extension of study duration until 2023 for all cohorts (except
      Genetic Registry).

      Amendment 12 - 01-Jun-2017 Planned date of trial extended to September 30, 2020 Ceasing new
      enrollments into the Genetic Registry for LRRK2 and GBA subjects Added Sensor - PPMI
      Companion Study Allow for consent to share contact information with FOUND team at any visit.
      Incorporation of Parkinson's Disease Risk Factor Questionnaire (PD-RFQ) into FOUND.

      Amendment 11 - 01-Apr-2016 Added the collection of peripheral blood mononuclear cells (PBMC)
      from blood samples at interim visits.

      Addition of PPMI Pathology Core/PPMI Brain and Tissue Bank Addition of Gait Assessment
      Companion Study (Select PPMI sites - Genetic Cohort only) Testing for additional GBA
      mutations - previously testing involved testing only for the GBA N370S mutation; however,
      going forward, testing will include tests for additional GBA mutations that are identified as
      being associated with certain ancestry.

      Amendment 10 - 05-Oct-2015 Extended study period for PD and Healthy Control subjects through
      8 years. For Prodromal subjects (RBD and Hyposmic) added iPSC companion study.

      Amendment 9 - 01-Nov-2014 Addition of GBA throughout to document additional testing for GBA
      mutation. Allocation of subjects in Genetic Cohort and Genetic Registry revised to account
      for inclusion of GBA subjects.

      Amendment 8 - 12-May-2014 Companion Protocols: skin biopsy/stem cell; Amyloid Imaging 18F
      Florbetaben; Family History Sub-Study; FOUND in PPMI registry. More detailed description of
      new procedures including: Advance directive for clinical research participation; Extension of
      study period (for SWEDDs with positive scans at Yr. 2) by continuing or re-inviting to study
      and followed (as per PD subjects through Month 60); Objective Parkinson Disease Measurement
      (OPDM) finger tapping measurement.

      Amendment 7 - 14-Oct-2013 Pre-Screening Prodromal - RBD clarifications Pre-Screening Genetic
      Cohort - clarified Assessments/tests clarified, including addition of consent (or withdrawal
      of consent, if applicable) for future contact about future studies and PD family history data
      collection for Genetic cohort subjects as selected visits.

      Amendment 6 - 29-May-2013 Genetics Coordination Core is added to study. The GCC included
      Genetic Cohort PD Subjects, Genetic Cohort Unaffected Subjects and Genetic Registry Subjects.

      Amendment 5 - 27-Nov-2012 Olfactory and RBD subjects added as the Prodromal cohort.

      Amendment 4 - 30-Mar-2012 Addition of 18F-AV-133 VMAT-2 PET Imaging for participating U.S.
      sites and Australia. (Refer to 18F-AV-133-PPMI companion protocol).

      Number of sites increased from 21 to 24. Addition of cognitive categorization and diagnostic
      features assessments.

      Amendment 3 - 15-Jul-2011 Addition of SWEDD subjects to study design. Blood Sampling
      Advisement to collect research samples in a fasted state.

      Amendment 2 - 19-May-2011 Changed visit window from 30 days to 45 days for Baseline visit to
      be completed.

      Section on DAT and SPECT Imaging - section changed to account for subject travel to the
      Institute for Neurodegenerative Disorders to conduct SPECT scanning and injection of either
      DaTSCAN or BCIT.

      Main Protocol - PPMI will be a five-year natural history study (a minimum of 3-year
      involvement for each subject) of de novo idiopathic PD patients and healthy controls. This
      study will also include a SWEDD (subjects without evidence of dopaminergic deficit)and
      Prodromal populations.

      All subjects will be comprehensively assessed at baseline and every three to six months
      thereafter. Subjects will undergo clinical (motor, neuropsychiatric and cognitive) and
      imaging assessments and will donate blood, urine, and cerebral spinal fluid (CSF). A blood
      sample for DNA will be collected. Data will be collected by each site under uniformly
      established protocols and data will be analyzed and stored at designated core facilities.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Rates of Change</measure>
    <time_frame>Baseline to 156 months</time_frame>
    <description>The mean rates of change and the variability around the mean of clinical, imaging and biomic outcomes in early PD patients, and where appropriate the comparison of these rates between PD patient subsets and between various subsets (including, but not limited to: PD vs. healthy subjects, PD vs. SWEDD, PD vs. prodromal, PD with and without LRRK2, GBA or SNCA mutation, unaffected LRRK2, GBA or SNCA mutation carriers vs. healthy controls) at study intervals ranging from 3 months to 36 months. Specific examples of outcomes include MDS-UPDRS, dopamine transporter imaging striatal uptake, vesicular monoamine transporter type-2 uptake, and serum and CSF alpha-synuclein. PD patient subsets may be defined by baseline assessments, genetic mutations, progression milestones and/or rate of clinical, imaging, or biomic change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between Rates of Change</measure>
    <time_frame>Study intervals ranging from 3 months to 156 months</time_frame>
    <description>Comparison between the rates of change in the mean of clinical, imaging and biomic outcomes in various subsets (including, but not limited to: early PD vs. healthy subjects, PD vs. SWEDD, PD vs. prodromal, PD with and without LRRK2, GBA or SNCA mutation, unaffected LRRK2, GBA or SNCA mutation vs. healthy controls)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of measures of clinical, imaging and biomic outcomes in various subsets (</measure>
    <time_frame>study intervals ranging from baseline to 156 months.</time_frame>
    <description>Including, but not limited to: early PD patients, healthy subjects, PD vs SWEDDs, PD vs prodromal, PD with and without LRRK2, GBA or SNCA mutation, unaffected LRRK2, GBA or SNCA mutation carriers vs. healthy subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive Value</measure>
    <time_frame>Baseline to 156 months</time_frame>
    <description>To establish the predictive value of early clinical non-motor features, baseline imaging and biomic outcomes for future course of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the proportion of SWEDD subjects that have a change in their clinical management at 24 months</measure>
    <time_frame>Baseline to 156 Months</time_frame>
    <description>SWEDD Clinical Diagnosis and Management Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Analysis</measure>
    <time_frame>Baseline to 156 months</time_frame>
    <description>Exploratory analysis to estimate the percentage of Prodromal subjects with one or more risk characteristics [hyposmia (&lt;10th percentile for age and gender), RBD, or LRRK2, GBA or SNCA genetic mutation, and baseline DaTSCAN binding showing minimal to moderate DAT deficit] that phenoconvert to PD within 2 years, and an exploratory analysis to examine whether the baseline DaTSCAN binding or progression of clinical, imaging, or biospecimen markers may predict those subjects likely to phenoconvert.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Datscan SPECT Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaTscan</intervention_name>
    <arm_group_label>Datscan SPECT Imaging</arm_group_label>
    <other_name>Ioflupane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Parkinson Disease (PD) Subjects:

          -  A diagnosis of Parkinson disease for 2 years or less at Screening.

          -  Confirmation from imaging core that screening DAT scan is consistent with dopamine
             transporter deficit, or if applicable a VMAT-2 PET scan consistent with vesicular
             monoamine transporter deficit.

          -  Not expected to require PD medication with at least 6 months from Baseline.

          -  Male or female age 30 years or older at time of PD diagnosis.

        Healthy Control (HC) Subjects:

        â€¢ Male or female age 30 years or older at Screening.

        Exclusion Criteria:

        Parkinson Disease (PD) Subjects:

          -  Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or other PD
             medication.

          -  Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days
             of Baseline.

          -  Has taken levodopa or dopamine agonists prior to Baseline for more than a total of 60
             days.

          -  Received any of the following drugs that might interfere with DAT imaging:
             Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or
             amphetamine derivative, within 6 months of Screening.

          -  Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
             safe completion of the lumbar puncture.

        If applicable, currently taking medications that are known to cause QT-prolongation, or are
        currently taking tetrabenazine (TBZ or amphetamine type medications.

          -  Condition that precludes the safe performance of routine lumbar puncture, such as
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
             coagulopathy or thrombocytopenia.

          -  Use of investigational drugs within 60 days prior to Baseline (dietary supplements
             taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10).

        Healthy Control (HC) Subjects:

          -  Current or active neurological disorder.

          -  First degree relative with idiopathic PD (parent, sibling, child).

          -  MoCA score &lt; 26.

          -  Received any of the following drugs that might interfere with DAT imaging:
             Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or
             amphetamine derivative, within 6 months of Screening.

        If applicable, currently taking medications that are known to cause QT-prolongation, or are
        currently taking tetrabenazine (TBZ) or amphetamine type medications.

          -  Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
             safe completion of the lumbar puncture.

          -  Condition that precludes the safe performance of routine lumbar puncture, such as
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
             coagulopathy or thrombocytopenia.

          -  Use of other investigational drugs within 60 days prior to baseline (dietary
             supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme
             Q10).

        SWEDD Subjects:

        All PD criteria apply, as above, except a SWEDD subject must have confirmation from imaging
        core that screening dopamine transporter SPECT scan shows no evidence of dopamine
        transporter deficit or if applicable a VMAT-2 PET scan shows no evidence of vesicular
        monoamine transporter deficit.

        Prodromal Subjects:

        Inclusion Criteria (Prodromal Subjects) 4.2.7.1. Subjects must have at least one of the
        following characteristics:

        Hyposmia:

          1. Male or female age 60 years or older

          2. Confirmation from olfactory core that olfaction as determined by UPSIT is at or below
             the 10th percentile by age and gender

        REM Behavior Disorder (RBD):

          1. Male or female age 60 years or older

          2. Confirmation from sleep core that subject's Polysomnography (PSG) meets criteria for
             RBD

        LRRK2:

          1. Male or female age 60 years or older

          2. Written confirmation or documentation from testing facility that the individual is
             LRRK2 mutation positive 4.2.7.2. Confirmation from imaging core that screening
             dopamine transporter SPECT scan is read as eligible (see below). About 80 subjects
             will have a range of DAT deficit similar to subjects with early PD (mild to moderate
             DAT deficit). About 20 subjects will be selected with no DAT deficit or minimal DAT
             deficit similar in age, gender, and risk profile to those with mild to moderate DAT
             deficit. 4.2.7.3. Ability to provide written informed consent in accordance with Good
             Clinical Practice (GCP), International Conference on Harmonization (ICH), and local
             regulations. 4.2.7.4. Willing and able to comply with scheduled visits, required study
             procedures and laboratory tests. 4.2.7.5. Women may not be pregnant, lactating or
             planning pregnancy during the course of the study. Includes a negative urine pregnancy
             test on day of screening scan prior to injection (DaTSCAN).

        Exclusion Criteria (Prodromal Subjects)

          1. Current or active clinically significant neurological disorder or psychiatric disorder
             (in the opinion of the Investigator).

          2. GDS score greater than or equal to 10 (GDS score of 5 - 9 requires Investigator
             discretion to enter study).

          3. STAI Form Y-1 greater than or equal to 54 requires Investigator discretion to enter
             study.

          4. A clinical diagnosis of dementia63 as determined by the investigator (Appendix 1).

          5. A clinical diagnosis of Parkinson disease at the Screening visit as determined by the
             Investigator.

          6. Received any of the following drugs that might interfere with dopamine transporter
             SPECT imaging: Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate,
             reserpine, or amphetamine derivative, within 6 months of Screening.

          7. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
             safe completion of the lumbar puncture.

          8. Condition that precludes the safe performance of routine lumbar puncture, such as
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
             coagulopathy or thrombocytopenia.

          9. Any other medical or psychiatric condition or lab abnormality, which in the opinion of
             the investigator might preclude participation.

         10. Use of investigational drugs or devices within 60 days prior to Baseline (dietary
             supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme
             Q10).

         11. Previously obtained MRI scan with evidence of clinically significant neurological
             disorder (in the opinion of the Investigator).

        Genetic Cohort: Parkinson Disease Subjects - Inclusion:

          1. Patients must have at least two of the following: resting tremor, bradykinesia,
             rigidity (must have either resting remor or bradykinesia) or either asymmetric resting
             tremor or asymmetric bradykinesia.

          2. A diagnosis of Parkinson Disease for 7 years or less at screening.

          3. Hoehn and Yahr state &lt;4 at baseline

          4. Male or female age 18 years or older

          5. Willingness to undergo genetic testing and to be informed of genetic testing results.

          6. Confirmation of mutation in LRRK2, GBA or SNCA

          7. For subjects taking any drugs that might interfere with dopamine transporter SPECT
             imaging (Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine or
             amphetamine derivative must be willing and able from a medical standpoint to hold the
             medication for at least 5 half-lives prior to screening DatSCAN(TM) imaging.

        Exclusion:

          1. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
             safe completion of the lumbar puncture.

          2. Condition that precludes the safe performance of routine lumbar puncture, such as
             prohibitive lumbar spinal disease, bleeding diathesis or clinically significant
             coagulopathy or thrombocytopenia.

        Genetic cohort - Unaffected Individuals

        Inclusion:

          1. Male or female age 45 years or older at baseline with LRRK2 or GBA mutation and/or
             first degree relative with a LRRK2 or GBA mutation or

          2. Male or female age 30 years or older at baseline with a SNCA mutation and/or a first
             degree relative with a SNCA mutation.

          3. Unaffected subjects at high risk of LRRK2, GBA or SNCA mutation due to first degree
             relative with a LRRK2, GBA or SNCA mutation may choose either to be informed of the
             results or remain unaware of the results.

          4. Unaffected subjects from an ethnic or geographic group knkown to have relatively high
             risk of LRRK2, GBA or SNCA mutation such as people of Ashkenazi Jewish or Basques
             descent) and who have a family member (either alive or deceased) who has/had PD must
             be willing to be informed of their own testing results.

          5. Willingness to undergo genetic testing

          6. For subjects taking any of the following drugs that might interfere with dopamine
             transporter SPECT imaging (neuroleptics, metoclopramide, alpha methyldopa,
             methylphenidate, reserpine or amphetamine derivative) must be willing and able from a
             medical standpoint to hold the medication for at least 5 half-lives prior to DatSCAN
             imaging.

        Exclusion:

          1. A clinical diagnosis of PD

          2. Current treatment with anticoagulants (e.g. coumadin, heparin) that might preclude
             safe completion of the lumbar puncture.

          3. Condition that precludes the safe performance of routine lumbar puncture, such as
             prohibitive lumbar spinal disease, bleeding diathesis or clinically significant
             coagulopathy or thrombocytopenia.

        Genetic Registry - Inclusion:

          1. Individual with a LRRK2, GBA or SNCA mutation and/or a first degree relative with a
             LRRK2, GBA or SNCA mutation.

          2. Male or female age 18 years or older

          3. Willingness to undergo genetic testing, but may choose either to be informed of the
             results or remain unaware of the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth L Marek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Q. Trojanowski, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur W. Toga, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana Froud, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Kieburtz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Trials Coordination Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Singleton, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratory of Neurogenetics; National Institute on Aging NIH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John P Seibyl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Coffey, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Trials Statistical and Data Management Center, University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0948</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Parkinson's Institute</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute For Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease&amp; Movement Disorder Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati/Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp;Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington and VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Sydney</city>
        <zip>NSW2109</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck Medical University</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena Klinik</name>
      <address>
        <city>Kassel</city>
        <zip>34128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foundation for Biomedical Research of the Academy of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11523</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Salerno</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Michael J. Fox Foundation for Parkinson's Research</investigator_affiliation>
    <investigator_full_name>Ken Marek, MD</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>Bio-markers</keyword>
  <keyword>Neurodegenerative disorder</keyword>
  <keyword>Imaging</keyword>
  <keyword>Prodromal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

